1360537-75-2

Basic information

• Product Name: 2-[⁽¹⁸⁾F]fluoro-4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide
• Synonyms: 2-[⁽¹⁸⁾F]fluoro-4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide
• CAS NO: 1360537-75-2
• Molecular Weight: 504.506
• Mol File: 1360537-75-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-[⁽¹⁸⁾F]fluoro-4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[⁽¹⁸⁾F]fluoro-4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide(1360537-75-2)
• EPA Substance Registry System: 2-[⁽¹⁸⁾F]fluoro-4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide(1360537-75-2)

Safety Data

• Hazardous Substances Data: 1360537-75-2(Hazardous Substances Data)

Upstream product

• 145369-94-4 6-bromo-3-quinolinecarboxylic acid-4-ol 
• 187278-01-9 5-(((4-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 152684-30-5 5-bromo-2-methoxy-3-nitropyridine 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 1086063-18-4 6-bromo-4-(pyridazin-4-yl)quinoline 
• 1360537-71-8 4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)-2-nitrobenzenesulfonamide 
• 1360537-69-4 N-(5-bromo-2-methoxypyridin-3-yl)-4-fluoro-2-nitrobenzenesulfonamide 
• 884495-39-0 5-bromo-2-(methyloxy)-3-pyridinamine 
• 1086062-75-0 6-bromo-4-chloroquinoline hydrochloride 
• 927801-23-8 6-bromo-4-iodoquinoline 
• 65340-70-7 6-bromo-4-chloroquinoline 
• 1242618-50-3 1-(benzylsulfanyl)-4-fluoro-2-nitrobenzene 
• 568586-10-7 4-fluoro-2-nitrobenzene-1-sulfonyl chloride 

Relevant articles and documents

[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers

GSK2126458 is a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) with low picomolar to subnanomolar activity. [11C]GSK2126458 and [18F]GSK212 6458, new potential PET agents for imaging of PI3K and mTOR in cancer, were first designed and synthesized in 40-50% and 20-30% decay corrected radiochemical yield, and 370-740 and 37-222 GBq/lmol specific activity at end of bombardment (EOB), respectively.